B
Beijing Qingke Biotechnology
A gene synthesis platform enterprise with an independent whole industry chain
About Beijing Qingke Biotechnology
Beijing Tsingke Biotechnology Co., Ltd. operates as a vertically integrated gene synthesis platform, establishing a significant footprint in the synthetic biology sector since its inception. Founded in 2017, the company is headquartered in Beijing, China, and has expanded its operations to include numerous laboratories and entities across the country, as well as extending its business to the United States and Germany. Tsingke serves a global client base of over 170,000 users, including academia, pharmaceutical companies, and research institutions.
The company's business model is structured around three core pillars: synthetic genomics products and services, life science research equipment and raw materials, and biomanufacturing as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO). This integrated approach allows Tsingke to control the entire gene synthesis industrial chain. Revenue is generated by providing a comprehensive suite of products and services, including oligo synthesis, gene synthesis, protein expression, and antibody services. The company has positioned itself as an upstream enterprise in the synthetic biology ecosystem, providing the foundational technologies and materials for the industry.
Tsingke has developed what it terms a "Gene Factory," an intelligent and automated production platform. This platform combines proprietary molecular resolution and synthesis technology with the TSINGKE HELIXTECH AI algorithm system to connect raw materials, equipment, and processes for efficient production. Key offerings include Tsynth™ Gene Synthesis, which can produce gene lengths up to 200 kb, and versatile oligo synthesis solutions with over 200 modifications. The company also provides services for protein expression, antibody production, gene regulation, and sequencing. This technological infrastructure is supported by a significant R&D site and a 100,000-grade clean production workshop.
Since its founding, the company has achieved significant financial milestones, securing a Series B funding round of over CNY 400 million (approximately $57 million) in December 2022. This funding, led by investors such as Henan Investment Group Huirong Fund and Fortune Capital, was earmarked for further R&D investment in its "gene factory," technology platform upgrades, talent acquisition, and global expansion. By January 2022, the company had also completed a Series A round, contributing to a total raised amount of over $87 million. Tsingke's commitment to innovation is evidenced by its portfolio of over 300 intellectual property rights.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Dec 2022 | $55M | $220M | Dachen Caizhi · Qingsong Capital · Capitallink · Henan Investment Group | ↗ |
Growth signals
Latest recorded traffic for Beijing Qingke Biotechnology is 29K monthly website visits, down 38.3% over the last three months. Beijing Qingke Biotechnology's team grew 8.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beijing Qingke Biotechnology in its local ecosystem
The Beijing Qingke Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
- DCDachen Caizhi
- QCQingsong Capital
- CACapitallink
- HGHenan Investment Group
- JBJinyu Bogor
- ZAZhongyuan Assets
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beijing Qingke Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beijing Qingke Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









